Orphazyme stock plummets following bad news from CHMP

The Danish biotech company is being punished on the stock exchange after the CHMP, an EMA expert committee, had a negative reaction to the company’s oral presentation on Wednesday.
Photo: Sydbank/PR
Photo: Sydbank/PR
by marketwire, translated by daniel pedersen

Orphazyme stock is down by 34 percent, dropping to DKK 9.2 (USD 1.4) per share.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading